Key result
Novel intraventricular axial flow pump demonstrates minimal hemolysis alongside reliable seal performance in preclinical testing.
Why the study?
The development of implantable axial flow blood pumps must address mechanically induced hemolysis and shaft seal reliability.
Population
Bovine and ovine blood in vitro and animal models in vivo
Comparison
New impeller design and purged seal system vs previous designs
Design
Preclinical in vitro hemolysis tests and in vivo animal tests
Authors
Loading...
Supports further LVAD engineering; hypothesis-generating and requires human trials before clinical consideration.
A novel intraventricular axial flow LVAD with an improved impeller and purged seal system showed promising hemocompatibility and seal reliability in preclinical testing.
Yamazaki et al. (1995) studied Heart failure (LVAD development). Intraventricular axial flow blood pump with new impeller and purged seal system was evaluated on Normalized index of hemolysis. A newly designed intraventricular axial flow blood pump demonstrated very low hemolysis (normalized index of hemolysis 0.0051 +/- 0.0047 g/100 L) in vitro and potential seal reliability in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: